ITI-1549

ITI-1549
Clinical data
Other namesITI1549
Routes of
administration		Unspecified
Drug classNon-hallucinogenic serotonin 5-HT2A receptor agonist
Identifiers
  • (6b'R,10a'S)-8'-[2-(1,2-benzoxazol-3-yl)ethyl]-2',3',6b',9',10',10a'-hexahydro-3'-methylspiro[cyclopropane-1,2'-[1H,7H]pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline]
Chemical and physical data
FormulaC25H28N4O
Molar mass400.526 g·mol−1
3D model (JSmol)
  • CN1c2cccc3c2N(CC12CC2)[C@H]1CCN(CCc2noc4ccccc24)C[C@@H]31
  • InChI=1S/C25H28N4O/c1-27-22-7-4-6-17-19-15-28(13-9-20-18-5-2-3-8-23(18)30-26-20)14-10-21(19)29(24(17)22)16-25(27)11-12-25/h2-8,19,21H,9-16H2,1H3/t19-,21-/m0/s1
  • Key:CQNKASRHJXEWTD-FPOVZHCZSA-N

ITI-1549 is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist of the pyridopyrroloquinoxaline family which is under development for the treatment of mood disorders and other psychiatric disorders. In addition to acting at the serotonin 5-HT2A receptor, it is also an antagonist of the serotonin 5-HT2B receptor and an agonist of the serotonin 5-HT2C receptor. The drug's route of administration has not been specified.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.